Jazz Pharmaceuticals PLC (JAZZ) Holdings Boosted by Atlantic Trust Group LLC

Atlantic Trust Group LLC raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 63,495 shares of the specialty pharmaceutical company’s stock after buying an additional 1,680 shares during the quarter. Atlantic Trust Group LLC owned 0.11% of Jazz Pharmaceuticals worth $9,287,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of JAZZ. Toronto Dominion Bank lifted its stake in Jazz Pharmaceuticals by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the period. US Bancorp DE increased its holdings in shares of Jazz Pharmaceuticals by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 368 shares in the last quarter. Advisor Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 62.4% during the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after acquiring an additional 550 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $211,000. Finally, Brighton Jones LLC bought a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $213,000. 90.73% of the stock is currently owned by hedge funds and other institutional investors.

JAZZ has been the subject of several recent research reports. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, August 29th. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, August 30th. Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, August 29th. Royal Bank of Canada restated a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, September 15th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 18th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $181.28.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $132.78 on Tuesday. Jazz Pharmaceuticals PLC has a 1-year low of $106.60 and a 1-year high of $163.75. The stock has a market capitalization of $8,000.00, a price-to-earnings ratio of 21.87, a P/E/G ratio of 0.86 and a beta of 0.97. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63.

In other Jazz Pharmaceuticals news, SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the completion of the transaction, the senior vice president now owns 28,383 shares in the company, valued at approximately $3,786,859.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Insiders have sold 18,552 shares of company stock valued at $2,549,643 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/12/26/jazz-pharmaceuticals-plc-jazz-holdings-boosted-by-atlantic-trust-group-llc.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit